Blueprint Medicines (BPMC) | Stock Overview & Key Data

Blueprint Medicines Corp. | Mid-cap | Healthcare

$127.96

-0.19%

| Blueprint Medicines Stock Comparison:

Blueprint Medicines vs Vertex Blueprint Medicines vs Regeneron Blueprint Medicines vs Roivant Sciences Blueprint Medicines vs Bio-Techne Blueprint Medicines vs Revolution Medicines Blueprint Medicines vs S&P 500 | Market

Chart Range Statistics Financials Returns Ownership Calculator FAQ

Blueprint Medicines Performance Comparison

Loading chart data...

Blueprint Medicines

Healthcare Sector

S&P 500

View Full Price History

Stock Range

Today's Range

Low: $127.94 High: $128.27

on June 13, 2025

52 Week Range

Low: $73.04 High: $128.34

on April 9, 2025

on June 11, 2025

All-Time High: $128.34 on June 11, 2025

Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights

Key Statistics

Market Cap i $8.3B

EPS i -2.51

P/E Ratio (TTM) i -119.59

Forward P/E i -136.13

P/B Ratio i 24.15

PEG Ratio i -136.13

Div. Yield i 0.00%

ROE i -47.71%

Beta i 0.833

Debt to Equity i 208.50

Financial Highlights

Profitability

Gross Margin i 98.12%

Operating Margin i -27.50%

Profit Margin i -27.70%

Returns and Earnings

Return on Assets (TTM) i -9.75%

Return on Equity (TTM) i -47.71%

EBITDA i $-158.4M

Net Income (TTM) i $-155.7M

Growth

Revenue (TTM) i

Revenue Per Share (TTM) i

Quarterly Revenue Growth i

Quarterly Earnings Growth i

Peer Performance Comparison

Company	Market Cap	1W	1M	3M	6M	YTD	1Y	3Y	5Y
Blueprint Medicines BPMC	8.27B Mid-cap	0.09%	28.73%	42.43%	37.31%	46.74%	21.23%	163.13%	62.39%
Vertex VRTX	116.96B Large-cap	1.10%	5.43%	-9.44%	-1.79%	12.25%	-5.26%	73.12%	55.30%
Regeneron REGN	57.14B Large-cap	7.30%	-7.82%	-22.24%	-27.63%	-26.00%	-48.94%	-8.90%	-17.81%
Roivant Sciences ROIV	7.70B Mid-cap	0.80%	5.20%	8.64%	-4.39%	-6.29%	5.89%	158.45%	14.11%
Bio-Techne TECH	7.92B Mid-cap	3.76%	-2.11%	-15.63%	-33.25%	-29.32%	-33.41%	-38.23%	-21.59%
Revolution Medicines RVMD	7.56B Mid-cap	-1.22%	1.60%	4.00%	-9.82%	-7.75%	5.10%	125.37%	7.81%

Ownership & Short Interest

Insider Ownership i 0.86%

Institutional Ownership i 109.42%

Shares Short i 6M

Short Ratio i 7.19

Short % of Shares Outstanding i 10.60%

Average 10-Day Volume i 11M

Average 90-Day Volume i 4M

Blueprint Medicines Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Blueprint Medicines would have performed over time.

Investment Amount

Investment Frequency

Start Date

End Date (Optional)

If not specified, the latest available data will be used

Reinvest Dividends

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

What is BPMC's 52-week high and low?

In the last 52 weeks, Blueprint Medicines reached a high of $128.34 (on June 11, 2025) and a low of $73.04 (on April 9, 2025).

What is the market cap and P/E ratio for BPMC?

Curious about Blueprint Medicines's size and valuation? Its market capitalization stands at 8.27B. When it comes to valuation, the P/E ratio (trailing twelve months) is -119.59, and the forward P/E (looking ahead) is -136.13.

Does BPMC pay dividends? If so, what's the yield?

As for dividends, Blueprint Medicines isn't currently offering a significant yield, or that specific data isn't available right now. Its payout ratio, which shows how much of its earnings are paid as dividends, is 0.00%.

Who are Blueprint Medicines's main competitors or similar companies to consider before investing?

When looking at Blueprint Medicines, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Vertex VRTX	116.96B	Healthcare	Biotechnology	-5.26%	73.12%
Regeneron REGN	57.14B	Healthcare	Biotechnology	-48.94%	-8.90%
Roivant Sciences ROIV	7.70B	Healthcare	Biotechnology	5.89%	158.45%
Bio-Techne TECH	7.92B	Healthcare	Biotechnology	-33.41%	-38.23%
Revolution Medicines RVMD	7.56B	Healthcare	Biotechnology	5.10%	125.37%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Blueprint Medicines Corp.? (e.g., ROE, Debt/Equity)

To get a sense of Blueprint Medicines's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -47.71%, the Debt to Equity ratio from the most recent quarter is 208.50, and its Gross Profit Margin stands at 98.12%.

What is the recent revenue and earnings growth for BPMC?

Looking at Blueprint Medicines's growth, its revenue over the trailing twelve months (TTM) was $562M. Compared to the same quarter last year (YoY), quarterly revenue grew by 55.50%, and quarterly earnings saw a YoY growth of -99.40%.

How much of BPMC stock is held by insiders and institutions?

Wondering who owns Blueprint Medicines stock? Company insiders (like executives and directors) hold about 0.86% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 109.42%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.